Twist Bioscience (NASDAQ:TWST) has announced the availability of two new SARS-CoV-2 antibody panels designed for research use only.
The first panel includes 32 human antibodies and targets SARS-CoV-2 spike protein.
The second panel includes 48 antibodies targeting extracellular domain of the ACE2 receptor on human cells, the receptor that facilitates entry of SARS-CoV-2 into the cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.